13 Jan 2016 --- Nestlé Health Science has signed an exclusive agreement outside the United States and Canada for Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics) in the fields of Clostridium difficile infections (CDI, such as SER-109 and SER 262) and Inflammatory Bowel Disease (IBD; such as SER-287 and SER-301). The agreement follows Nestlé Health Science’s initial equity investments in US-based Seres Therapeutics (NASDAQ: MCRB) announced in January and July 2015.
